https://www.bioworld.com/COVID19products

Lists 554 Therapeutics and 171 vaccines.

Apabetalone is listed as a pre-clinical therapeutic

Synairgen is listed as a Phase II therapeutic

15 compounds in "compassionate use" status

3 more with emergency use authorization

Plus one submitted for same, and another revoked.

7 for "expanded access - either in studies or approved - 1 tagged as "no benefit"

Then there are Phase IV, Phase III, Phase II/III, Phase II, Phase I/II, Phase I, Pre-clinical, and Discovery categories.

 Just a snapshot of the playing field for COVID treatment

 In a more detaled table at https://www.bioworld.com/COVID-19-therapeutics-vaccines

The status noted for Apabetalone is given as:

"Seeking to collaborate with organization currently testing therapies for SARS-CoV-2, the virus responsible for COVID-19, in preclinical or clinical models; Apabetalone is designed to prevent specialized proteins, bromodomain and extraterminal domain proteins, from activating the expression of disease-associated and other genes; as of June 1, Resverlogix said it is moving forward with a plan to evaluate apabetalone, first investigating whether it impacts the replication cycle of the virus and then assessing safety and efficacy in an open-label study"